Dendrite Enters into Serious Adverse Event Reporting Contract with Pfizer Inc.; Multi-Year, Multi-Million-Dollar Contract Covers All Clinical Trials.

Business/Health & Medical Editors

MORRISTOWN, NJ--(BUSINESS WIRE)--Oct. 23, 2001

Dendrite (NASDAQ/NMS: DRTE), the visionary innovator in global pharmaceutical technology, today announced that Pfizer Global Research and Development (PGRD) has awarded Dendrite's Clinical Trial Services division a multi-year, multi-million-dollar contract. Under the agreement, Dendrite will facilitate all serious adverse event reporting for PGRD's entire line of worldwide clinical trials. Dendrite will provide a 24x7 multilingual clinical support center and facilitation in order to support reporting.

"Serious adverse event reporting is one of the most important, but often most challenging areas, during the clinical trial process," said William Van Nostrand, Senior Vice President of Dendrite's Clinical Trial Services division. "By using the processes and services to be provided by Dendrite, serious adverse reports will be accurately recorded in a timely manner."

The contract extends Dendrite's current relationship with Pfizer to support Pfizer clinical trials. In April, Dendrite announced that Dendrite would act as the primary facilitator for all connectivity logistics at each investigative site where Dendrite's full services would be used to support both Pfizer's internally developed Electronic Data Capture System (EDC) and the company's clinical trials site management system. The agreement includes the provision of a multilingual clinical support center, hardware acquisition and deployment, software loading and validation, and support of their web portal site management system. This system includes regulatory documentation, drug medication distribution, grant payments to investigators, and patient randomization scheduling through interactive voice response.

About Dendrite

Dendrite, the innovator in global pharmaceutical technology, helps clients strategically manage customer relationships to increase market share. The company creates unique, analytically driven solutions that enable pharmaceutical companies to influence prescriber behavior, thereby delivering a sustained competitive advantage. More than 80,000 pharmaceutical sales representatives and their managers from over 150 companies and 57 countries use Dendrite products and services. They represent 19 of the top 20 pharmaceutical companies. For more information, visit www.dendrite.com.

About Dendrite Clinical Trial Services

Dendrite's Clinical Trial Services division decreases the time and cost of clinical trials by enabling pharmaceutical companies to outsource the management and support of e-R&D technologies resources such as EDC and site management. It provides state-of-the-art products and services to streamline patient randomization, mobile data capture, document, management, and investigator coordination; and offers patient and physician recruitment services using proprietary data and analytic engines. It delivers e-learning services that provide web-based delivery of distance instruction and collaboration for investigators, CRCs, and CRAs.

Note: Dendrite is a registered trademark of Dendrite International, Inc.

The foregoing contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The statements may be identified by such forward-looking terminology as "expect," "believe," "may," "will," "intend," "plan," and similar statements or variations. Such forward-looking statements are based on our current estimates and assumptions and involve certain significant risks and uncertainties, including: risks associated with and dependence on the pharmaceutical industry; fluctuations in quarterly revenues due to lengthy selling cycles, product implementation cycles, customer budget cycles, and timing of revenue recognition; dependence on major customers; successful and timely development and introduction of new products and versions; rapid technological changes; increased competition; retention of key senior managers; and unique characteristics of the consumer packaged goods industry. Other important factors that should be considered are included in the company's 10-K, 10-Qs, and other reports filed with the SEC. Actual results may differ materially. The company assumes no obligation for updating any such forward-looking statements.